- Home
- SFST vs ADCT Comparison
SFST vs ADCT Comparison
Compare SFST & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFST
- ADCT
- Stock Information
- Founded
- SFST 1999
- ADCT 2011
- Country
- SFST United States
- ADCT Switzerland
- Employees
- SFST N/A
- ADCT N/A
- Industry
- SFST Major Banks
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- SFST Finance
- ADCT Health Care
- Exchange
- SFST Nasdaq
- ADCT Nasdaq
- Market Cap
- SFST 285.9M
- ADCT 241.0M
- IPO Year
- SFST 1999
- ADCT 2020
- Fundamental
- Price
- SFST $39.38
- ADCT $2.79
- Analyst Decision
- SFST Buy
- ADCT Strong Buy
- Analyst Count
- SFST 1
- ADCT 6
- Target Price
- SFST $43.00
- ADCT $7.80
- AVG Volume (30 Days)
- SFST 15.9K
- ADCT 921.7K
- Earning Date
- SFST 07-17-2025
- ADCT 08-05-2025
- Dividend Yield
- SFST N/A
- ADCT N/A
- EPS Growth
- SFST 37.29
- ADCT N/A
- EPS
- SFST 2.25
- ADCT N/A
- Revenue
- SFST $97,501,000.00
- ADCT $75,817,000.00
- Revenue This Year
- SFST $4.07
- ADCT $10.65
- Revenue Next Year
- SFST $8.99
- ADCT $15.05
- P/E Ratio
- SFST $17.37
- ADCT N/A
- Revenue Growth
- SFST 11.95
- ADCT 10.49
- 52 Week Low
- SFST $27.65
- ADCT $1.05
- 52 Week High
- SFST $45.91
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- SFST 64.65
- ADCT 49.36
- Support Level
- SFST $35.15
- ADCT $2.55
- Resistance Level
- SFST $40.09
- ADCT $2.98
- Average True Range (ATR)
- SFST 1.02
- ADCT 0.28
- MACD
- SFST 0.30
- ADCT -0.11
- Stochastic Oscillator
- SFST 86.58
- ADCT 16.90
About SFST Southern First Bancshares Inc.
Southern First Bancshares Inc is a bank holding company. The company engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer and mortgage loans to the general public of which a majority of the revenue is derived from the Commercial and Retail Banking segment which includes the provision of traditional deposit and lending products and services to its commercial and retail banking clients.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).